CA
NZ
UK
AU
IND
US
● The primary endpoint showed adverse events in 56.5 percent of VYD2311 recipients over six days, versus 91.4 percent for vaccine.
● Phathom began screening patients on September 29, 2026 in pHalcon-NERD-302, a randomized Phase 3 trial of as-needed VOQUEZNA 10 mg.
● Oncolytics furnished a press release on a PNAS paper about pelareorep in hepatocellular carcinoma, published September 28, 2026.
● Scilex amended its revolving line ofCreditto Vivasor, raising the maximum amount under the note from $20,000,000 to $30,000,000.
● Aldeyra intends to file a Formal Dispute Resolution Request with the FDA in the fourth quarter of 2026.
● A prospective study of Renuvion in patients undergoing facelift surgery was published in Plastic and Reconstructive Surgery Global Open.
● Moleculin completed enrollment of Part A of its MIRACLE trial, with 89 subjects enrolled and one more in screening.
● uniQure furnished a September 29, 2026 8-K with 36-month and 48-month follow-up for AMT-130, its Huntington's disease gene therapy.
● Five patients with generalized myasthenia gravis were retreated with Descartes-08 at a median of 16.6 months after initial treatment.
● Summit will issue 108,955.3686 shares of Class A Convertible Preferred Stock at $18,356.14 each, for $2.0 billion in gross proceeds.
Please wait processing your request...